Tumor Microenvironment

Cancer immunotherapy has the great potential to achieve long-term survival in patients with a solid malignancy. However, the beneficial effect of cancer immunotherapy is seen in only a minority of patients. Mounting evidence suggests that immunosuppressive features in the tumor microenvironment prevent an effective antitumor defense. The aim of the investigators is to comprehensively analyze the cytokine profile and the tumor immune infiltrate in the tumor microenvironment and to investigate its prognostic significance in patients with radically resected lung adenocarcinoma.

Active, not recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Lung Adenocarcinoma Adenocarcinoma Adenocarcinoma of Lung Carcinoma Lung Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Lung adenocarcinoma
Tumor stage IB and II
With or without adjuvant therapy
Complete surgical resection (R0)
No distant metastasis at the time of surgery (M0)

Exclusion criteria

Second cancer within 5 years

Treatment and study plan

Primary outcomes

Overall survival

Time frame: From date of surgery until the date of death from any cause assessed up to 100 months

Association of tumor microenvironment with overall survival

Secondary outcomes

Recurrence-free survival

Time frame: From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Association of tumor microenvironment with recurrence-free survival

Sponsors and collaborators

Lead sponsor

University Hospital Heidelberg

Other

Registry information

Official study title

Tumor Microenvironment in Lung Adenocarcinoma

Important dates

Study start: 2016
Primary completion: 2026
Study completion: 2026
First posted: Aug 8, 2023
Registry last updated: May 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, not recruiting